Quanterix Extends Oncology Footprint with Accelerated Launch of Next Gen SP-X™ Platform and CorPlex™ Validated 10-Plex
Following successful beta program, theSimoa SP-X next generation benchtop and CorPlex are launching ahead of schedule to further revolutionize cancer research, immunotherapy monitoring, and drug development
For the first time, researchers are able to access over one thousand assay configurations of critical immunomodulatory biomarkers for oncology research with multiplexing up to 10-plex without sacrificing sensitivity. The broad assay menu covers more than 50 analytes and enables researchers to easily develop custom homebrew assays, further extending the range of applications to include PK/PD and immunogenicity assays as well. Simoa CorPlex assays undergo extensive validation, providing one of the most highly validated assay menus in the industry, ensuring customers can utilize the assays in the most demanding clinical and translational research applications. The next generation Simoa planar array technology utilized in CorPlex assays promotes non-invasive biomarker measurements, supporting easier and more approachable methods for determining drug efficacy and toxicity. This addresses the previously unmet needs of oncology researchers, particularly in the rapidly expanding fields of immuno-oncology and immunotherapy, including checkpoint inhibitors and CAR-T cell therapies.
“Immuno-oncology-based treatments have long shown tremendous promise for
improving how we treat cancers, but researchers have lacked reliable
methods to test the efficacy and toxicity of those treatments early in
therapeutic intervention,” said
While immunotherapies have gained traction as a promising way to treat many cancers, the inability to optimize dosing and the occurrence of immune-related adverse events have hindered progress. Critical biomarkers that would enable researchers to make informed decisions with respect to dosing and toxicities are often at such low concentrations that the reliable measurement has been problematic until now. With Simoa CorPlex assays, researchers can measure concentrations of key circulating cytokines and immunological biomarkers across all stages of disease progression including normal healthy baseline levels. This means that researchers will be able to more quickly see whether the immunotherapy or other cancer treatments are working, or potentially avoid severe side effects such as neurotoxicity and cytokine release syndrome. This means the Simoa CorPlex could have the potential to catalyze dramatic reductions in treatments costs, which can amount to several hundred thousand dollars a year.
General availability of Simoa CorPlex is made possible by the SP-X Imaging and Detection System, Quanterix’ new state-of-the-art benchtop imager that utilizes a proprietary planar array technology, offering advanced multiplexing capabilities with the same Simoa sensitivity found in the company’s HD-1 and SR-X instruments. Building on the success of Quanterix’ flagship Simoa technology, the SP-X and Simoa CorPlex are meeting the needs of oncology researchers with the goal of revolutionizing patient care.
About
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Words
such as "may," "will," "expect," "plan," "anticipate," "estimate,"
"intend" and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are intended to
identify forward-looking statements. Forward-looking statements in this
news release include statements relating to the promise of the SP-X and
Simoa CorPlex to revolutionize oncology research and drug development
and are based on Quanterix’ expectations and assumptions as of the date
of this press release. Each of these forward-looking statements involves
risks and uncertainties. Factors that may cause Quanterix’ actual
results to differ from those expressed or implied in the forward-looking
statements in this press release are discussed in Quanterix’ filings
with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20190110005527/en/
Source:
Lindsay Poole
PAN Communications
617-502-4300
quanterix@pancomm.com